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Introduction
Atopic eczema (also termed atopic dermatitis or eczema1,2) is an 
itchy inflammatory skin disorder with complex and multifactorial 
aetiology3. The phenotype is heterogeneous and pathogenic 
mechanisms vary between affected individuals4. The pathogen-
esis may include differential contributions of: immune activation 
and skin barrier dysfunction; local and systemic effects; multiple 
genetic and environmental factors5. Loss-of-function muta-
tions in FLG, encoding filaggrin, cause the common Mendelian 
disorder of keratinization, ichthyosis vulgaris (OMIM # 146700). 
FLG null mutations are also strongly associated with increased 
risk of atopic eczema6,7 and multiple other atopic traits8–10.
Skin is an organ that can be modelled in vitro to effectively 
recapitulate the multi-layered structure and gene expression 
patterns of human skin in vivo11. This offers the opportu-
nity for selected molecular mechanisms to be investigated 
in relative isolation from a complex disease state, using 
relevant primary cells. Replicate experiments can be performed 
using primary cells with the same genetic background or cells 
from different donors12. Detailed functional and biochemical 
analyses may then be applied to define potential therapeutic 
targets12,13.
Filaggrin is a marker of keratinocyte differentiation; it is 
expressed in the granular layer of the upper epidermis as a 
polymer – profilaggrin – which undergoes post-translational 
modification and stepwise proteolysis to release monomeric 
filaggrin14. Profilaggrin and filaggrin have multiple functions, 
each of which have been described as contributing to the mechani-
cal, biochemical, immunological and microbiological aspects 
of skin barrier function15. Clinical studies have shown that filag-
grin haploinsufficiency is associated with xerosis and ichthyo-
sis (dry and scaly skin), keratosis pilaris (increased keratin 
within skin follicles), palmar hyperlinearity16 and increased 
transepidermal water loss17. Transcriptomic analysis of full thick-
ness skin biopsies have shown evidence of an abnormal defence 
response in FLG haploinsufficient atopic skin18; proteomic 
analysis to assess the effect of FLG knockdown in an epider-
mal organoid has also shown features of inflammation and stress 
protease activity19. However, in vitro studies have not shown 
consistent histological or functional effects of filaggrin defi-
ciency in the various different skin organoid models published 
to date20 and the multiple mechanisms by which filaggrin 
deficiency contributes to atopic disease remain incompletely 
understood5.
We have optimised a skin organoid model, with dermal and 
epidermal compartments cultured using donor-matched primary 
cells, for functional assessments and global mass spectrom-
etry proteomic analysis. The work aims to investigate in more 
detail the effect of FLG siRNA-mediated knockdown on one cell 
type - the keratinocyte - to increase understanding of the filag-
grin-deficient phenotype and to further define molecular 
mechanisms predisposing to atopic skin inflammation.
Methods
Source of primary human cells
Primary keratinocytes and primary fibroblasts were isolated 
from human skin tissue samples obtained, with written informed 
consent and Ethical Committee approval (East of Scotland 
Research Ethics Service reference 17/ES/0130 renewal 12/
ES/0083) under governance of the Tayside Biorepository. Surgical 
surplus samples of clinically normal skin from four adult donors 
(all females aged 29–65 years; one abdominal and three breast skin 
reductions) were used for the organoid cultures. Similar samples 
(n=5) were used for independent biological replicates to test 
for reproducibility of the functional effects of FLG knockdown.
Organoid culture methods
Primary keratinocytes and dermal fibroblasts were isolated 
from human skin by sequential trypsin EDTA and collagenase 
D digestion21. Using our previously reported methods12, the 
keratinocytes were co-cultured with mitomycin C inactivated 
3T3 feeder cells in RM media (3:1 DMEM : Hams F12, 10% 
FCS, 0.4µg/ml hydrocortisone, 5µg/ml insulin, 10ng/ml EGF, 
5µg/ml transferrin, 8.4ng/ml cholera toxin and 13ng/ml liothy-
ronine) (Sigma Aldrich, Gillingham, Dorset, UK)22. Epidermal 
growth factor (EGF) was omitted for the first day of culture. 
The fibroblasts were cultured in DMEM supplemented 
with 10% FCS under standard conditions.
Fibrin gel dermal equivalents12 were prepared using 0.5ml 
fibrinogen (35 mg/ml in NaCl) (Sigma Aldrich, Gillingham, 
            Amendments from Version 1
The main aim of this publication is to facilitate sharing of the 
global mass spectrometry data generated from the skin organoid 
models with FLG knockdown (described in detail) and functional 
analyses (described and reported); this main aim has been 
clarified.
In response to the interest from Reviewers 1 and 3, we have 
provided an explanation as to why knockdown of FLG at mRNA 
level is demonstrated to a lesser degree than the knockdown 
at protein level, reflecting the prolonged duration (10 days) of 
organoid culture.
We have emphasised that increased dye penetration was 
observed in some but not all of the immature organoids, as 
requested by Reviewer 1.
Additional details have been provided to explain how the protein 
false discovery rate was determined for the removal of false 
positives, as requested by Reviewer 1.
We have included a fuller explanation of the analysis approach, 
in which we focus on consistent differences observed across the 
biological replicate experiments and use thresholds for increased 
and decreased expression to include roughly equal numbers of 
proteins.
We have corrected the use of the terms ‘ratio’ and ‘fold-change’ 
where necessary.
A new Figure 10 is provided, following advice from reviewer 2. 
The colour-coding has been removed and we have labelled 
selected data points. During revision of this figure we discovered 
an error in the plotting of this figure; this detail has been corrected 
in the revised Methods section and in the re-drawn volcano plot.
The title has been modified to include the term ‘full thickness’, to 
clarify the complexity of our model (as recommended by reviewer 
2). The list of main findings has now been removed from the title 
because it had become too long.
Minor typos have been corrected, including two references 
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Dorset, UK) and 0.5ml thrombin (3U/ml in 2 mM CaCl2 / 1.1% 
NaCl) (Sigma Aldrich, Gillingham, Dorset, UK) combined on 
ice, with 200,000 fibroblasts and aprotinin (0.1 U/ml) (Sigma 
Aldrich, Gillingham, Dorset, UK) then transferred to a 12-
well plate. After 30 minutes incubation at 37°C, the gels were 
covered in medium (DMEM, 10% FCS, 0.1 U/ml Aprotinin) and 
cultured overnight (day 1). On day 2, the medium was replaced 
with RM excluding EGF, 0.1U/ml aprotinin and 2 × 106 
suspended keratinocytes. Culture medium was refreshed daily 
on days 3 and 4 using RM containing 0.1ng/ml EGF and 
0.1U/ml aprotinin. On day 5 the gels were carefully removed 
from wells and lifted onto custom-made steel grids lined with 
nylon gauze (Millipore, Livingston, Scotland, UK). RM medium 
supplemented with 0.1ng/ml EGF and 0.1U/ml aprotinin was 
added up to the base of the dermal equivalent so that the epidermis 
remained at the air-liquid interface. Medium was refreshed 
on alternate days sand the cultures were used for analysis up 
to day 12 (representing three, five and seven days after lifting 
to the air-liquid interface).
A diagrammatic summary of the process of skin organoid culture 
is shown in Figure 1.
Epidermis was separated from the fibrin gel using hyper-
tonic saline-induced split (4 hours, 1M NaCl, 4°C) to obtain a 
keratinocyte-only tissue sample for biochemical analyses.
FLG genotyping
DNA was extracted from donor skin samples using stand-
ard techniques and genotyping was performed for the four 
Figure 1. Diagrammatic summary of skin organoid culture. Dermal and epidermal equivalents produced using our published methodology 
optimised for skin barrier assessment12.
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most prevalent loss-of-function mutations in FLG in this white 
European population (R501X, 2282del4, R2447X and S3247X)23 
using validated KASPTM technology (LGC Genomics, Hod-
desdon, Hertfordshire, UK), as previously reported4,24. Briefly, 
KASPTM SNP genotyping consists of two competitive, allele-
specific forward primers and one common reverse primer. 
Each forward primer incorporates an additional tail sequence 
that corresponds with one of two universal FRET (fluores-
cent resonance energy transfer) cassettes (FAM and HEX). 
ROX™ passive reference dye, Taq polymerase, free nucle-
otides and MgCl2 in an optimised buffer solution make up 
the reaction master mix.
siRNA mediated knockdown
Keratinocytes were reverse transfected immediately prior to 
inclusion in the organoid cultures using RNAiMax transfec-
tion reagent (Life Technologies, Carlsbad, California, USA) 
according to manufacturer’s instructions. Briefly, siRNA com-
plexes were formed in OPTIMEM medium (20uM siRNA, 5µl 
RNAiMAX) and following 20 minutes incubation, combined with 
2 × 106 suspended normal human keratinocytes and trans-
ferred to the pre-prepared dermal substrate. A pool of four 
siRNA duplexes was used [FLG: LQ-021718-00-0002, Control: 
ON-TARGETplus non-targeting siRNA #4 D.001810-04-20] 
(Dharmacon, Lafayette, Colorado, USA).
Quantitative PCR
RNA was extracted from organoid epidermis using the Direct-
zol RNA kit (R2071, Zymo Research, Irvine, California, 
USA) following homogenisation in RNA-Bee (CS-104B, 
Amsbio, Abingdon, Oxfordhire, UK) using the TissueLyser LT 
(Qiagen, Manchester, UK) 5 mins at 50 Hz. cDNA was prepared 
from 1µg total RNA using random priming (2.5µM final) 
(Integrated DNA Technologies, Coralville, Iowa, USA) in com-
bination with Moloney murine leukemia virus (MMLV) enzyme 
(100 units) and buffer systems (28025013, Life Technologies, 
Carlsbad, California, USA). qPCR reactions were performed 
using exon spanning probe-based assays (FLG: 
HS.PT.58.24292320FAM, EF1A: HS.PT.58.24345862FAM) [Inte-
grated DNA Technologies, California, USA]) with TaqMan gene 
expression Mastermix (4369016, Life Technologies, Carlsbad, 
California, USA). Reactions were prepared and run using the 
Qiagility robot in combination with the Rotor-Gene Q 
(Qiagen, Manchester, UK). EF1A was used as a reference gene. 
PCR cycling conditions were: 95°C for 10 mins, [95°C for 
15 seconds, 60°C for 60 seconds] × 40 cycles. Fold changes 
were derived via the 2(-Delta Delta C[T]) method.
Western blotting
Organoid epidermis was homogenized in RIPA buffer (Cell 
Signalling Technologies, London, UK) using the TissueLyser 
LT (Qiagen, Manchester, UK) 5 mins at 50 Hz. Protein lysates 
were normalized by Pierce BCA assay (23225, Thermo Fisher, 
Waltham, Massachussets, USA) and resolved under reducing 
conditions using the NuPage® gel electrophoresis system (Life 
Technologies, Carlsbad, California, USA). Primary antibodies 
(monoclonal mouse filaggrin [RRID: AB_1122916, catalogue # 
sc66192, Santa Cruz Biotechnology, Texas, USA] and monoclonal 
mouse GAPDH [RRID: AB_2756824, catalogue # 97166, 
Cell Signalling Technologies, Boston, USA]) were prepared 
in 5% bovine serum albumin (BSA) and incubated overnight 
at 4°C with agitation. Immunoblots were developed using 
either goat anti rabbit (P0448, RRID: AB_2617138) or goat 
anti mouse (P0447, RRID: AB_2617137) peroxidase con-
jugated secondary antibodies (DAKO, Glostrup, Denmark, 
1:5000) in combination with chemiluminescent HRP substrate 
(Immobilon, Millipore, Billerica, Massachussets, USA) onto 




Formalin-fixed, paraffin embedded full thickness organoids 
were sectioned and stained using haematoxylin and eosin and 
imaged using Visiscope LT384P (VWR International, Lutterworth, 
UK).
(ii) Transmission electron microscopy (TEM)
Organoid skin samples were fixed in 4% paraformaldehyde, 
2.5% gluteraldehyde in 0.1M sodium cacodylate buffer (pH 
7.2) for one hour then cut into small pieces, washed in buffer 
and post-fixed in 1% osmium tetroxide in cacodylate buffer 
for one hour or 1% ruthenium tetroxide in cacodylate buffer 
for one hour. The pieces were dehydrated through alcohol 
series, into propylene oxide and embedded in Durcupan resin. 
Ultrathin sections were stained with 3% aqueous uranyl acetate 
and Reynold’s lead citrate and examined on a JEOL 1200EX 
electron microscope. TEM images were collected on a SIS 
Megaview III camera.
Functional assessments
(i) Trans-epidermal water loss (TEWL)
Organoid cultures were equilibrated at room temperature and 
atmospheric conditions for 30 minutes before TEWL was 
measured at two locations on the epidermal surface using an 
Aquaflux AF200 instrument (Biox Systems Ltd, London, 
UK) with a closed chamber and a custom (5mm diameter) 
probe head. TEWL measurements were taken every second 
for a minimum of 60 seconds until a stable reading, as 
determined by the software, was obtained. TEWL directly 
measures water evaporation from the skin surface but it may 
be considered as a measurement of ‘inside-outside’ barrier 
function25.
(ii) Capacitance
To inform the interpretation of TEWL, we measured electri-
cal capacitance; this is directly proportional to water content 
of the uppermost 10–20µm of tissue. Organoid cultures were 
equilibrated at room temperature and atmospheric condi-
tions for 30 minutes prior to measurement of epidermal surface 
capacitance, using a CorneometerTM and multiprobe adapter 
(CM825 and MPA2, Courage and Khazaka, Cologne, Germany). 
Three measurements were recorded from each organoid and the 
mean was calculated.
(iii) Fluorescent dye penetration
50µl of 1mM lucifer yellow dye (Sigma Aldrich) was 
added to the epidermal surface of the organoid and incubated at 
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37°C for 4 hours. Metal cloning rings were used to control 
uniform dosing on the epidermal surface. The lucifer 
yellow was removed and the organoids washed in PBS before 
formalin fix-paraffin embedding under standard conditions. 
4µM sections were deparaffinized, counterstained with DAPI 
(1µg/ml for 10 mins) (Life Technologies, Carlsbad, California, 
USA) and imaged by confocal Zeiss LSM710 microscope. 
Quantification of dye penetration in the upper dermis (average 
intensity in upper 40µm) was performed using Zeiss Zen Blue 
lite version 2.3 software and compared using paired t-tests. Dye 
penetration represents a measurement of the ‘outside-inside’ 
barrier function.
Mass spectrometry proteomic analysis
Frozen organoid epidermal samples were ground on dry ice, 
solubilized in 200µl of Cellular and Organelle Membrane 
Solubilizing Reagent (C0356-4BTL, also called Protein Extrac-
tion Reagent Type 4, Sigma-Aldrich, Gillingham, Dorset, UK), 
7.0 M urea, 2.0 M thiourea, 40 mM Trizma® base (Sigma Aldrich, 
Gillingham, Dorset, UK) and 1.0% C7BzO, pH 10.4 buffer 
with protease inhibitors. The lysate was acetone precipitated 
for 1 hour at -20°C and spun for 20 mins at 2°C at 15,000 rpm. 
The pellet was re-suspended in 200µl of 50mM ammonium 
bicarbonate. 100µl was taken for in-solution digest. 22µl of 
dithiothreitol was added and samples heated to 50°C for 15mins. 
24µl of iodoacetamide was added and the samples incubated 
at 22°C for 30 mins. 1µl of RapiGestTM (186001860, Waters, 
Herts, UK) was added, followed by 2.5µl of trypsin, for a 
12-hour digest. A further 1µl trypsin was added for an 
additional 4-hour digest. The peptide samples were fractionated 
into 24 fractions with high pH Reversed Phase C18 chromatog-
raphy, run on a Q Exactive Classic or Plus for 160 mins and the 
top 15 ions selected for sequencing. Mass spectrometry 
resolution was 70,000 and tandem mass spectrometry (MS/MS) 
resolution 17,500. Data were processed using MaxQuant 
(v1.6.0.13) and Human UniProt Database (Dec 2017) with a 
protein and peptide false discovery rate of 0.01.
Proteins identified as contaminants (trypsin and other lab 
originating proteins) and contained within the MaxQuant 
database were removed. To account for the possibility of 
keratin as a contaminant, we analysed the blank runs for 
keratin peptide intensity and subtracted this from the measured 
keratin intensities. A reversed database was used to identify false 
positives. The peptide and protein false discovery rate was set 
at 1%, and these were removed from further analysis.
Total intensities of the samples were normalized to total pro-
tein abundance, with adjustment to the lowest total protein 
yield. All samples were run in quadruplicate and reproducibility 
was assessed by Pearson correlation.
Mass spectrometry lipidomic analysis
Organoid samples were sonicated in phosphate buffered saline 
(pH7.4) and then extracted according to the method of Folch 
et al.26. The samples were analysed by liquid chromatography- 
mass spectrometry (LC-MS) on a Thermo Exactive Orbitrap 
mass spectrometer (Thermo Scientific, Hemel Hempsted, UK) 
coupled to a Thermo Accela 1250 ultra high pressure liquid 
chromatography (UHPLC) system. Samples were injected on to 
C18 column (Thermo Hypersil Gold, 2.1 mm x 100 mm, 1.9 µm) 
and separated using a water/acetonitrile/isopropanol gradient27. 
Ceramide 17:0 (Avanti Polar Lipids, Alabaster, AL, USA) 
was included as an internal standard. Ion signals correspond-
ing to individual ceramide molecular species were extracted 
from raw LC-MS data sets. Concentration of ceramide was 
expressed as pmol/mg after normalisation to mg of wet weight 
tissue.
Data analysis of qPCR, immunoblotting and functional 
assessments
Measurements were compared between non-targeting control- 
treated organoid models and FLG-siRNA-treated models, 
using paired t-test.
Histological sections of 10 replicate skin organoid experiments 
were measured using a standardized technique to minimize 
bias, as follows: three points were measured on each slide, at 
the right side, middle and left of each sample, across viable cell 
layers and stratum corneum; measurements were generated using 
Fuji ImageJ (May 2017) and the mean of the three measurements 
calculated.
Proteomic data analysis
The total intensities of the samples were normalised to total pro-
tein abundance, with adjustment to the lowest total protein yield. 
Log2 ratio of protein expression (log2 FLG knockdown – log2 
NT control) was visualised as a volcano plot, using GraphPad 
Prism (version 5) for human proteins detected in (three or all 
four) of the replicate experiments. P values were calculated 
by paired t-test applied to log 10 transformed data. Because 
of the burden of multiple testing in this large dataset, rather than 
defining arbitrary thresholds for ‘statistical significance’, our 
analyses focussed on changes that showed consistency across 
the biological replicate experiments. Approximately 1000 of the 
>8000 proteins were selected as showing consistently increased 
or decreased abundance, defined as follows:
Proteins were considered to be reduced in abundance if they 
showed a reduction in all four biological replicate experi-
ments comparing FLG-knockdown organoid samples to 
matched non-targeting controls and ratio ≤0.5 in three or four 
out of four of the replicates and reduced to undetectable levels 
of protein in a maximum of two replicates. Proteins were con-
sidered to be increased in abundance if they showed an increase 
in all four biological replicate experiments comparing FLG-
knockdown organoid samples to matched controls treated with 
non-targeting controls and ratio ≥1.2 in three or four out of four 
of the replicates. These magnitudes of change were used to 
define roughly equal proportions of up- and down-regulated pro-
teins for pathway analysis. The groups were then assessed using 
gene ontology and network analysis in STRING, version 1128 
and pathway prediction  using the Reactome Knowledge-
base, version 6829. This analysis, based on consistency of find-
ings across multiple biological replicate experiments was used 
in preference to a defined threshold of statistical significance, 
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Figure  2.  qPCR  analysis  of  epidermis  from  skin  organoids 
with and without FLG siRNA-mediated knockdown. Probes and 
primers are listed in Methods; n=8 biological replicates; error bars 
show SEM; *paired t-test p<0.05.
Figure  3.  Quantification  of  filaggrin  in  organoid  epidermis.  (A) Representative western blot. (B) Approximated quantification by 
densitometry. NT, non-targeting; n=7; ***p<0.0005 compared to non-targeting control.
with the aim to identify proteins and pathways of importance 
in the context of a common complex but heterogenous trait.
Lipidomic data analysis
The ratio of ceramide and omega-hydroxy ceramide species 
were compared between the FLG knockdown organoids and 
matched control samples in five biological replicate experiments.
Results
All samples are wild-type for the prevalent FLG null 
mutations and filaggrin shows knockdown at mRNA and 
protein level
Genotyping of DNA from tissue samples from the four skin 
donors did not detect any of the prevalent FLG null mutations30; 
this does not, however, exclude the possibility of rare 
(<0.01 allele frequency) null mutations.
FLG knockdown in the skin organoids persisted to day 10 
after siRNA transfection, as demonstrated by qPCR (Figure 2) 
and western blotting (Figure 3). We note the greater magni-
tude of knockdown quantified at mRNA than protein level in the 
organoid epidermis 10-days after transfection. This is likely to 
reflect the inherent differences in mRNA and protein stabilities: 
FLG mRNA has a half-life of ~2.2 hours31 whereas the half-lives 
of profilaggrin and filaggrin are approximately 6 and 24 hours 
respectively32.
FLG knockdown results in morphological changes in the 
epidermis
Histological examination confirmed a reduction of the 
granular layer, in keeping with a reduction in profilaggrin 
(Figure 4A). There was also a slight reduction in thickness 
of the stratum corneum (ratio 0.83 +/- 0.05 (mean +/- SEM), 
but no difference in thickness of the keratinocyte cell layers 
(Figure 4B).
Transmission electron microscopy (TEM) of the skin organoid 
model shows an effective recapitulation of the physiological 
layers of keratinocyte differentiation within skin, including a 
mature, multi-layered stratum corneum with corneodesmosomes 
and a granular layer with keratohyalin granules and desmo-
somes (Figure 5A). TEM of the FLG-knockdown organoid 
shows a similarly mature epidermis, but the stratum corneum 
has fewer layers and the granular layer contains keratohyalin 
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Figure 4. Structural changes in organoid models. (A) Histological examination (representative images from 8 biological replicates). NT, 
non-targeting. (B) Measurement of relative thickness of epidermal layers: VCL, viable cell layer and SC, stratum corneum; n=8; compared 
using paired t-test; **p<0.005.
Figure 5. Ultrastructural features of control and FLG knockdown organoids. (A) Control organoid sample, showing elements of normal 
human skin structure including stratified differentiation. (B) Organoid with FLG siRNA-mediated knockdown, showing thinner stratum corneum, 
reduced prominence if the corneodesmosomes and desmosomes, and smaller keratohyalin granules (organelles containing profilaggrin).
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Figure  6.  Transepidermal  water  loss  (TEWL)  measurements. 
TEWL measured under standard conditions at days 3, 5 and 7 after 
the organoid is lifted to the air-liquid interface, using an Aquaflux 
AF200 instrument (Biox Systems Ltd, London, UK) with a 5mm 
diameter probe head. NT, non-targeting; N=5; error bars show 
SEM.
Figure  7.  Epidermal  capacitance  measurements.  Electrical 
capacitance, directly proportional to water content of the uppermost 
10–20µm of tissue, was measured under standard conditions at days 
3, 5 and 7 after the organoid is lifted to the air-liquid interface, using 
a CorneometerTM (Courage and Khazaka, Cologne, Germany); the 
mean of three measurements is recorded. NT, non-targeting; N=5; 
error bars show SEM; paired t test **p<0.005.
Figure 8.  Lucifer  yellow dye penetration of organoid samples. 
The hydrophilic lucifer yellow dye (Sigma Aldrich) was added 
to the epidermal surface of the organoid and incubated at 37°C 
for 4 hours before sectioning for microscopic examination. (A) 
Representative image from three of the five biological replicate 
experiments showing delayed maturation of barrier function. (B) 
Dot-plot of densitometry data from all five biological replicates. NT, 
non-targeting.
granules that are generally smaller and less numerous than in the 
control organoid (Figure 5B).
FLG knockdown shows some evidence of a barrier defect 
in the immature organoids but no functional effect on skin 
barrier in the mature organoid model
The organoid model described here shows progressive devel-
opment of skin barrier function after lifting to the air-liquid 
interface: there is a progressive reduction in TEWL (Figure 6), 
progressive reduction in capacitance (Figure 7) and the hydrophilic 
dye, lucifer yellow, is excluded from the epidermis by day 7 
in both the control and FLG-knockdown organoids (Figure 8).
Results from five biological replicate experiments showed there 
was no difference in the mean TEWL (Figure 6), or mean capaci-
tance measurements (Figure 7) between the mature organoid 
models with FLG knockdown and donor-matched non-targeting 
siRNA-treated controls. Capacitance was increased in the immature 
FLG-knockdown model (day 5 after air-exposure, Figure 7) 
and lucifer yellow dye was not fully excluded by the stratum 
corneum in some of the the FLG-knockdown replicate experi-
ments until day 7 (Figure 8). However, this delay in maturation 
of the ‘outside-to-inside’ barrier function was not consistently 
demonstrated in all biological replicates.
Mass spectrometry proteomic analysis identifies over 8000 
protein species per sample
After removal of contaminants and false positive results, >8000 
proteins were identified in each epidermal sample. The pro-
teomic data have been deposited to the ProteomeXchange 
Consortium via the PRIDE33 partner repository with dataset 
identifier PXD014875. Quality control analysis confirmed that 
similar distributions of proteins were identified in each experi-
ment (Figure 9A); protein extracts were analysed in quadru-
plicate to test for technical reproducibility and the Pearson 
correlations were 0.869-0.938 (Figure 9B).  The protein expression 
changes were visualised using a volcano plot (Figure 10).
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Figure  9.  Mass  spectrometry  proteomic  analysis  quality  control  assessments.  (A) Histograms showing the distribution of proteins 
quantified in each experiment. Bins on the x-axis contain the log2 intensity-based absolute quantification (iBAQ, sum of intensities of tryptic 
peptides for each protein divided by number of theoretically observable peptides); normalised counts of the proteins in each bin are shown on 
the y-axis; MS2, MS3, MS5 and MS6 are biological replicate experiments from different human donors; mock, untreated control organotypic; 
C4, non-targeting control treated organotypic; Filaggrin, FLG si-RNA treated organotypic. (B) Correlation of protein abundance from replicate 
analyses. x and y axes show iBAQ intensities of samples mapped against replicate analysis; biological replicates are highly correlated 
(Pearson correlation coefficient ≥0.86).
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Figure 10. Volcano plot to visualise changes in protein expression between control and FLG siRNA-treated organoids. Adjusted protein 
intensity data were filtered to include only human proteins detected in three or four replicate experiments. The log2 ratio (log2 FLG knockdown 
– log2 NT control) for each donor was calculated and averaged; p-values from paired t-test were derived from log10 transformed data and are 
unadjusted. Selected data-points with more extreme values are labelled using the abbreviated protein name. NT, non-targeting.
648 proteins show a consistent reduction in expression in 
skin organoids with FLG knockdown
648 human proteins showed a reduction in expression in all four 
of the replicates and ratio ≤0.5 in three out of four replicates. 
This list is available as Underlying data, uploaded to Figshare30.
645 of the proteins are identified in STRING and this group 
showed significant enrichment for interactions (p<1.0e-16) com-
puted by combining the probabilities from the different evi-
dence channels and corrected for the probability of randomly 
observing an interaction21. Gene ontology (GO) analysis in 
STRING showed evidence for functional enrichment of GO-
terms including RNA processing (false discovery rate (FDR) 
4.40e-11), catalytic activity (FDR 8.59e-08) and intracel-
lular component (FDR 3.88e-26). A list of the 10 most sig-
nificant GO analysis results in each of the GO domains is 
shown in Table 1 (see Underlying data)34.
Pathway analysis of down-regulated proteins identifies 
themes including RNA metabolism, adaptive immunity and 
axon guidance
Reactome detected 39 pathways in this set of proteins 
(Table 2, Underlying data)35. Descriptions include: metabo-
lism of RNA (including 67 out of the 652 genes in this pathway, 
FDR 3.36e-12); class I MHC mediated antigen processing and 
presentation (30/365 genes in pathway, FDR 0.0031); and axon 
guidance (34/541 genes, FDR 0.0207).
Down-regulated proteins indicate molecular mechanisms 
of relevance to atopic eczema
Manual searching of the list of down-regulated proteins iden-
tified several of specific interest based on a priori knowledge 
of eczema pathomechanisms. These highlight several puta-
tive therapeutic targets: the aryl hydrocarbon receptor plays 
a role in signalling pathways for skin barrier repair22 and has 
been proposed as a therapeutic target for the treatment of skin 
inflammation36; caspase 14 plays a role in filaggrin processing37 
and is required for epidermal protection against water loss and 
UVB-induced damage38; dermokine is a soluble regulator of 
keratinocyte differentiation39; sequence similarity to a murine 
protein (UniProtKB:Q8R1R3) indicates that StAR-related lipid 
transfer protein 7 may play a role in protecting mucosal tis-
sues from exaggerated allergic responses; a reduction in the 
cytokine TGF-beta 1 may predispose to atopic eczema40; 
and loss-of-function mutations in CYP4F22 cause lamellar 
ichthyosis41, suggesting that a reduction in CYP4F22 protein 
expression may contribute to the ichthyotic phenotype observed 
in ichthyosis vulgaris and atopic skin.
376 proteins show a consistent increase in expression in 
organoids with FLG knockdown
376 human proteins showed an increase in expression in 
all four of the replicates and ratio ≥1.2 in three or four out 
of the four replicates. This list is available as Underlying 
data, uploaded to Figshare30.
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374 proteins are identified in STRING and the group showed 
significant enrichment for interactions (p<1.0e-16). GO analy-
sis revealed enrichment of terms including translation (FDR 
4.12e-19), RNA binding (FDR 9.77e-12) and cytoplasmic 
part (FDR 9.64-36). A list of the 10 most significant GO 
analysis results in each of the GO domains is shown in Table 3 
(see Underlying data)42.
Pathway analysis of up-regulated proteins identifies 
themes including translation, innate and adaptive immunity 
and axon guidance
Reactome detected 113 pathways in this set of proteins with 
FDR p<0.05 (Table 4, Underlying data)43. Descriptions include: 
Translation (including 44 out of the 288 genes in this path-
way, FDR 1.17e-21); innate immune system (47/1012 genes in 
pathway, FDR 9.90e-7); cytokine signalling in immune system 
(32/654 genes in pathway, FDR 5.16e-05); and axon guidance 
(40/541, FDR 4.69e-11).
Up-regulated proteins indicate molecular mechanisms of 
relevance to atopic eczema
Manual searching of the list of up-regulated proteins identi-
fied several of relevance to atopic eczema, including: STAT1, an 
intracellular signalling molecule that shows increased expres-
sion in atopic eczema, and as part of the JAK-STAT pathway 
is targeted by several traditional herbal remedies44 as well as 
novel small molecule therapies45; carbonic anhydrase 2, which 
is increased in skin in a variety of forms of eczema46; 
and FK binding protein, which binds to tacrolimus, an 
established topical treatment for atopic eczema.
The type I keratins 10, 16 and 17 each show increased expres-
sion in the FLG-siRNA-treated organoid models with 
mean ratio 1.7, 1.3 and 1.3, respectively. Keratin 10 is an 
intermediate filament protein of structural importance in the 
skin; keratin 16 is an epidermis-specific keratin that plays a role 
in innate immunity in response to skin barrier breach47; kera-
tin 17 is expressed in epidermal appendages, including the hair 
follicle.
Finally, it is noteworthy that GAPDH, which is often considered 
to be a stable ‘housekeeping’ gene, is in the dataset of consist-
ently up-regulated proteins. However, in the context of this 
work, filaggrin knockdown is clearly apparent at a greater 
magnitude than the more subtle change in GAPDH (Figure 3).
Epidermal ceramide content shows no significant 
difference in FLG-knockdown organoids compared with 
controls
Ceramide and omega-hydroxy ceramide species in five bio-
logical replicate experiments showed no consistent difference 
between the FLG knockdown organoids and matched control 
samples (Figure 11).
Discussion
The functional and biochemical analyses of a filaggrin-deficient 
skin model have provided findings that are consistent with our 
and others’ previous analyses in vitro19 and in vivo48. We have 
included both epidermal and dermal compartments in this 
model (to allow for dermal-epidermal cross-talk49,50) and our 
more detailed proteomic analysis has revealed additional 
evidence of molecular mechanisms with relevance to atopic 
skin. These datasets are shared as a resource for the research 
community. 
Analysis of the immature organoid identified a delay in epi-
dermal maturation following FLG knockdown, but the lack of a 
replicable functional effect in our model, when mature, reflects 
previous reports in which epidermal equivalents created from 
FLG-null keratinocytes do not show impairment in barrier 
function20. This is in keeping with the observation that FLG-
null mutations are not fully penetrant with respect to ichthyosis 
vulgaris or atopic eczema16,51.
Because of the nature of our data, generated using biologi-
cal replicate samples, and the focus on modelling a common 
complex trait with considerable inter-individual variation, 
we elected to use the criterion of consistency across the bio-
logical replicates to define proteins of interest, followed by 
network and pathway analyses. We recognise that other, more 
complex data analytical approaches may be applied, and/or 
more focussed interrogation of specific pathways; we share 
the proteomics data and welcome such further analysis.
Our analysis has highlighted aspects of keratinocyte-immune 
signalling. This is an important component of the immuno-
logical barrier that may be overlooked in tissue with multiple 
different cell types. The predicted pathways entitled ‘innate 
immunity’ and ‘adaptive immunity’ included proteins showing 
Figure  11.  Ratio  of  ceramides  and  omega-hydroxy  ceramides 
in  organoid  epidermis. Dots represent values for five individual 
experiments; bars show 95% confidence interval.
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both increased and decreased expression (Table 2 and Table 4, 
Underlying data)35,43. This immune dysregulation is likely to 
contribute to the predisposition to infection and inflammation 
observed in filaggrin-deficient skin in vivo: filaggrin-deficient 
patients show increased viral infection of the skin52 and increased 
incidence of irritant53,54 and allergic contact dermatitis55. 
The regulation of innate and adaptive immune pathways 
within keratinocytes (in addition to cells of the haematopoietic 
lineage) may therefore represent a worthwhile target for future 
therapeutic interventions.
The lack of effect of FLG knockdown on the ceramide content in 
the model epidermis is also consistent with previously reported 
findings in vitro56,57 and in vivo58. We did not analyse in detail 
the other epidermal lipids and therefore we cannot comment on 
whether there were relevant changes. Differences in lamellar 
body structure59 have been reported in FLG-mutant skin biopsies 
but this was not clearly observed in the organoid model. How-
ever, ultrastructural examination of the model stratum corneum 
did reveal abnormalities in the lamellar bilayer structure and 
less prominent corneodesmosomes (Figure 5), as previously 
reported in vivo59. It is also noteworthy that pathway analy-
sis in Reactome identified the terms ‘metabolism of lipids’ and 
‘phospholipid metabolism’ from the group of consistently 
down-regulated proteins (Table 4, Underlying data)43.
The most significant themes identified in the groups of pro-
teins showing increased expression upon FLG knockdown 
relate to RNA binding and translation; this is in contrast to RNA 
metabolism and RNA processing, which are demonstrated in 
the proteins showing decreased expression. The functional sig-
nificance of this increase in transcriptional and translational 
activity cannot be determined from the gene ontology and path-
way analysis. We may hypothesise that it reflects the increased 
‘stress’ response, as we have previously observed in FLG geno-
type-stratified transcriptome analysis of atopic skin biopsies18 
and/or the activation of innate and adaptive immune mechanisms.
It is tempting to speculate that the increased expression of 
keratins 10 and 16 may contribute to palmar hyperlinearity 
and keratin 17 may contribute to keratosis pilaris. These are 
characteristic features of ichthyosis vulgaris but their 
pathogenesis has not yet been explained as a direct result of 
filaggrin haploinsufficiency16,60.
Several of the proteins showing reduced expression relate 
to aspects of differentiation, including filaggrin itself, and 
caspase 14 which plays a role in the terminal degradation of 
filaggrin37. The aryl hydrocarbon receptor (AhR) is a ligand- 
activated transcription factor that responds to multiple different 
environmental and metabolic stimuli to control transcriptional 
pathways of relevance to atopic eczema, including immunity and 
differentiation61. Activation of AhR reduces skin inflammation62 
and enhances barrier repair63; therefore, a reduction in AhR 
expression in the FLG knockdown organoid would be antici-
pated to increase the eczema diathesis by opposing these effects. 
AKT1 activity is known to be reduced in atopic skin, leading 
to an alteration in protease expression and reduced filaggrin 
expression and processing64. This mechanism may further 
exacerbate the filaggrin deficiency in our FLG knockdown 
organoid. Dermokine acts as a soluble regulator of keratinocyte 
differentiation and mice deficient in the epidermal dermokines 
(beta and gamma isoforms) show defective cornification65. 
Transforming growth factor (TGF) beta-1 is a multifunctional 
protein: it regulates the growth and differentiation of multiple 
cell types, including keratinocytes and it can promote 
either Th17 or T-regulatory cell lineage differentiation in 
a concentration-dependent manner; it appears to have an 
immunosuppressive effect in atopic disease since a genetically-
determined lower production of TGF-beta-1 is associated with 
increased risk of atopic dermatitis40.
The Reactome term ‘axon guidance’ was detected in proteins 
showing increased and decreased expression. It has long been 
recognised that there is an increase in the density of sensory 
neurons in eczematous skin66 and nerve growth factor expres-
sion is upregulated in the keratinocytes of patients with atopic 
eczema67. Therefore, dysregulation of axon guidance may be 
of relevance to the pruritus that is so characteristic of atopic 
eczema and contributes substantially to the morbidity of this 
condition3. Antagonists of transient receptor potential vanilloid 
subfamily member 1 (TRPV1), expressed on sensory nerves 
and keratinocytes, are now being investigated for the control 
of pruritus68,69.
Taken together, our data demonstrate that filaggrin haploinsuf-
ficiency leads to abnormalities in both structural and immune 
features within the keratinocyte compartment of the epidermis. 
Keratinocytes display immune activity, producing multiple 
cytokines and chemokines in addition to their roles in innate 
immunity70,71. Together with the evidence of dysregulation in 
axon guidance, these findings indicate that patients with filaggrin 
deficiency – either haploinsufficiency or a reduction in filaggrin 
expression that occurs secondary to atopic inflammation72 – may 
derive clinical benefit from future therapies targeting 
keratinocyte-immune crosstalk mechanisms and neurogenic 
pruritus.
The skin organoid model described here represents a valu-
able opportunity to study genetic effects on keratinocytes in 
relative isolation. However, the lack of other cell types (nota-
bly T cells, B cells, dermal dendritic cells and innate lymphoid 
cells), the absence of complex dermal structures (including 
neurons and blood vessels) and skin appendages (for example 
hair follicles, sweat and sebaceous glands) is also a limitation 
in that it precludes assessment of the complex interactions that 
are likely to occur between different tissue compartments in skin.
In conclusion, we share these experimental results in detailed 
form, because of the additional insight provided by this in vitro 
analysis of filaggrin deficiency in a skin organoid model; 
our findings compliment and extend previous work in vitro 
and in vivo. Our  analyses have re-emphasised the role of 
keratinocyte-specific mechanisms in contributing to immune and 
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neurological as well as structural aspects of skin barrier func-




Mass spectrometry proteomics data deposited in the Pro-
teomeXchange Consortium via the PRIDE partner repository33, 
Accession number PXD014875: https://identifiers.org/pride.
project:PXD014875
Figshare: Proteomic analysis of FLG knockdown in skin 
organoid. https://doi.org/10.6084/m9.figshare.c.4606052.v330.
This project contains the following underlying data:
-    TEM images (zip file containing raw, unedited TEM 
images in .tif format)
-    TEWL and corneometer readings (raw readings in .xlsx 
format)
-    Western blots (zip file containing unedited western blot 
scans, plus an annotated composite image with labels in .tif 
format)
-    Lucifer yellow dye penetration quantification.xlsx
-    Lucifer yellow dye penetration (zip file containing 
raw, unedited microscopy images for five replicates in 
.czi format)
-    Histology quantification (raw histology quantification 
data in .xlsx format)
-    H&E images (raw, unedited histology images for replicates 
1-11 in .bmp and .tif format)
-    Filaggrin densitometry (densitometry measurements for 
seven replicate experiments in .xlsx format)
-    FLG qPCR data (raw qPCR data in .xlsx format)
-    FLG genotyping results (raw genotyping results in .xlsx 
format)
-    Consistently down-regulated proteins in FLG kd organoids.
xlsx
-    Consistently up-regulated proteins in FLG kd organoids.
xlsx
Figshare: Table 1. Gene Ontology (GO) analysis of pro-
teins showing a consistent reduction in expression with FLG 
knockdown. https://doi.org/10.6084/m9.figshare.9710585.v134.
Figshare: Table 2. Reactome pathway analysis of down-regulated 
proteins. https://doi.org/10.6084/m9.figshare.9710666.v135.
Figshare: Table 3. Gene Ontology (GO) analysis of proteins show-
ing a consistent increase in expression with FLG knockdown. 
https://doi.org/10.6084/m9.figshare.9710738.v142.
Figshare: Table 4. Reactome pathway analysis of up-regulated 
proteins. https://doi.org/10.6084/m9.figshare.9710783.v143.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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The authors highlight the proteins that have relevance to the known pathogenetic mechanisms of
eczema. It would be helpful to emphasise the novel findings detected in this model compared to
the prior proteomic analysis published on filaggrin knockdown keratinocytes (Elias et al., 20171),



























Table 2 presents Reactome data and highlights Axon guidance, and it would be helpful to see this
in the context of the other pathways described. I would favour this being included in the PDF, rather
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The volcano plot (Fig 10) is of interest, but more data could be presented here, for example, the 7
points which are log2 fold change >+5 could be identified to make this more informative for the
reader. I am uncertain if the colour scheme with p value cut offs is helpful; the authors carefully
justify using selected fold change thresholds in the methods section over arbitrary thresholds that






Could the title be improved to reflect the more complete nature of this skin equivalent model that
incorporates fibroblasts? Also, how were the three elements "increased
transcriptional-translational activity, keratinocyte-immune crosstalk and disordered axon guidance”




























There is a minor typographical error on page 3. “Medium was refreshed on alternate day sand the
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The filaggrin knock-down at the RNA level was only approximately 50%, whereas the knock-down
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It is impossible to see obvious differences in Lucifer yellow penetration and there is also no










The proteomics data provide a very important resource. It would have been helpful to show the
validation of some of the data using independent samples and another method, e.g. Western blot









A comparison of the data with available transcriptomics data from AD patients would be interesting.
We agree that this would be a very interesting analysis; it is not within the remit of this study but we
or others may pursue this in the future.
For the proteomics analyses, it is not clear how the false discovery rate was exactly determined








Statistical analysis to identify proteins with differential abundance between conditions lacks
stringency and appears asymmetric with regard to positive and negative effect sizes. Lack of
statistically significant hits upon multiple testing correction is a common problem with proteomics
datasets. Which multiple testing correction algorithm was applied? Bonferroni or
Benjamini-Hochberg? Did the authors try e.g. a limma moderated t-test that has proven useful for
proteomics data? Even without multiple testing correction, a statistical test appears more suitable
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Moreover, the authors apply a cut-off of 2-fold (0.5) to identify proteins with lower abundance upon
filaggrin knockdown and of 1.2-fold (1.2) for those with higher abundance in this condition. It
appears this skewed effect size has been selected aiming at equalizing hit numbers for pathway









The terms ‘ratio’ and ‘fold-change’ are not used properly, since the authors report actual ratios as
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